Gabapentin for Personal Injury Cases: What Attorneys Need to Know

Amar Lunagaria — Co-Founder & Chief Pharmacist, LienScripts | December 11, 2025 | 9 min read

Gabapentin is one of the most frequently prescribed medications in personal injury cases. Understanding why it's prescribed, what it treats, and how it supports medical necessity arguments is essential knowledge for every PI attorney.

Gabapentin in Personal Injury: An Overview

Gabapentin is one of the most commonly prescribed medications in personal injury cases. After accident-related injuries involving nerve compression, whiplash, disc herniation, or traumatic soft tissue damage, physicians frequently turn to gabapentin to manage neuropathic pain — pain that originates from damaged or irritated nerve tissue rather than from the injury site itself.

For personal injury attorneys, gabapentin in a client's pharmacy record is a clinical signal worth understanding. It indicates that the treating physician identified nerve involvement in the injury — a finding that significantly affects case value, duration of treatment, and the medical necessity argument supporting the demand.

According to FDA prescribing information for gabapentin capsules, the drug is approved for postherpetic neuralgia and adjunctive therapy for partial seizures. In personal injury practice, gabapentin is widely prescribed off-label for neuropathic pain following traumatic injury — a use supported by substantial clinical evidence in peer-reviewed literature.

[!KEY] Gabapentin in a client's prescription history is not just a medication — it is clinical evidence of nerve involvement. It counters defense arguments that characterize the injury as "minor soft tissue" with no structural consequence.

Why Physicians Prescribe Gabapentin After an Accident

Gabapentin works by binding to the alpha-2-delta subunit of voltage-gated calcium channels in the central and peripheral nervous system. This binding reduces the release of excitatory neurotransmitters — including substance P and glutamate — that drive neuropathic pain signaling.

After a traumatic injury, several mechanisms can trigger the kind of nerve pain that gabapentin addresses:

Nerve root compression — Herniated discs at the cervical or lumbar spine can compress nerve roots, producing radiating pain, numbness, and tingling in the arms or legs. This radiculopathy pattern responds to gabapentin.

Peripheral nerve injury — Direct trauma to extremities can injure peripheral nerves, producing allodynia (pain from non-painful stimuli) and hyperalgesia (exaggerated pain response). Both patterns are targeted by gabapentinoids.

Central sensitization — After persistent injury, the central nervous system can become hypersensitized, amplifying pain signals even from areas that have structurally healed. Gabapentin modulates this central sensitization.

Post-traumatic neuropathy — Crush injuries, lacerations, and fractures can directly damage nerve tissue, producing chronic neuropathic pain requiring long-term gabapentinoid therapy.

The DailyMed prescribing information for gabapentin documents the drug's mechanism of action at alpha-2-delta calcium channel subunits — the same mechanism that underlies its off-label effectiveness for post-traumatic neuropathic pain, a use well-supported in peer-reviewed literature and endorsed by standard of care in pain medicine.

Gabapentin Prescribing Patterns in PI Cases

Understanding how and when gabapentin appears in a PI client's treatment timeline helps attorneys make sense of the medical records and anticipate defense arguments.

Initial Prescription

Gabapentin is often introduced after early conservative treatment (NSAIDs, muscle relaxants) fails to adequately control pain. If a patient's pain persists past 4–6 weeks after injury, or if they report radiating symptoms, tingling, or burning sensations, a physician will typically add a gabapentinoid to the regimen.

The initial dose is usually low (100–300 mg daily) and titrated upward based on response. Standard therapeutic doses for neuropathic pain range from 1,800 mg to 3,600 mg daily in divided doses.

Dose Titration and Duration

Because gabapentin has a saturable absorption mechanism (higher doses produce proportionally smaller increases in blood levels), physicians often titrate slowly and may plateau at a dose that is tolerated rather than the maximum labeled dose. This titration period typically spans 2–6 weeks.

Ongoing treatment duration depends on the underlying injury. Radiculopathy from a disc herniation may resolve with time and physical therapy, allowing gabapentin to be tapered after 3–6 months. Central sensitization or chronic neuropathy may require 12+ months of treatment.

[!NOTE] Extended gabapentin prescribing — 6 months or more — is clinically significant. It indicates that the treating physician found no adequate substitute and continued to believe the medication was necessary. This duration counters "soft tissue only, fully resolved" defense arguments.

Combination Therapy

Gabapentin is frequently prescribed alongside other injury medications. Common combinations in PI cases include:

• Gabapentin + cyclobenzaprine (nerve + muscle pain)
• Gabapentin + meloxicam (nerve + inflammatory pain)
• Gabapentin + amitriptyline (neuropathic pain with sleep disruption)
• Gabapentin + a topical agent (systemic + localized pain coverage)

Multi-drug regimens indicate complex injury presentations that resist simple first-line treatment. They support higher damages arguments.

Gabapentin vs. Pregabalin: Which Appears in PI Cases?

Both gabapentin and pregabalin target the same receptor system and treat the same conditions. The choice between them is driven by clinical preference and formulary availability.

Key differences:

• Pregabalin (Lyrica) has linear, predictable absorption — dose-response is reliable
• Gabapentin has saturable, nonlinear absorption — higher doses require more careful management
• Pregabalin is Schedule V controlled; gabapentin's scheduling varies by state
• Pregabalin was historically available only as brand Lyrica; generic pregabalin is now widely available

In personal injury cases, gabapentin is more commonly prescribed because it has been available generically longer and carries a well-established clinical track record. Pregabalin appears more often in catastrophic injury cases with complex neuropathic presentations.

For a detailed side-by-side clinical comparison, see our gabapentin vs. pregabalin guide for personal injury.

Gabapentin Records in the Demand Package

When a personal injury client is prescribed gabapentin, every fill becomes part of the pharmacy record that supports the demand package.

What the gabapentin record shows:

• Date the drug was first prescribed (establishing when nerve symptoms appeared)
• Dose progression (titration indicates the physician was actively managing inadequate pain control)
• Duration of treatment (establishes chronicity and seriousness of nerve involvement)
• Refill continuity (no gaps indicates consistent adherence; gaps require explanation)
• Drug interactions (gabapentin plus multiple other agents = complex injury)

[!KEY] Dose titration in the gabapentin record — a sequence of increasing fills from 300 mg to 1,800 mg or more over several weeks — documents that the physician found initial dosing insufficient to control symptoms, directly countering any defense argument that the nerve pain was mild or resolved quickly.

The pharmacy record is distinct from the medical record but corroborates it. A physician's chart note saying "patient reports radiating arm pain, starting gabapentin" is supported by the corresponding pharmacy fill on the same date. The two records together are stronger than either alone.

When medications are filled through a pharmacy lien program like LienScripts, a POGOS report (Pharmacy-Organized General Occurrence Summary) is available at settlement. For a gabapentin case, the POGOS provides:

• Pharmacist narrative connecting gabapentin to the documented injury mechanism
• Drug utilization review confirming appropriate use for neuropathic pain
• Timeline showing prescription start, titration, and duration
• Attestation from a licensed pharmacist

This clinical documentation significantly strengthens the medical necessity argument for the gabapentin cost in the lien.

Defense Attacks on Gabapentin — and How to Respond

Defense counsel sometimes challenges gabapentin in demands for two reasons: the off-label nature of its use for post-traumatic neuropathy, and its scheduled or controlled status in some jurisdictions.

Challenge: "Gabapentin is not approved for traumatic nerve pain — it's a seizure drug."

Response: Gabapentin is FDA-approved for postherpetic neuralgia — a neuropathic pain indication. Off-label use for neuropathic pain from traumatic injury is supported by robust clinical literature and standard of care. The prescribing physician's judgment that this medication was appropriate for this patient's symptoms is entitled to medical deference.

Challenge: "Gabapentin is a drug of abuse — your client was just seeking opioids."

Response: Gabapentin is not classified as a Schedule II–IV controlled substance by the DEA. Its abuse classification varies by state. More importantly, the prescription was ordered by a treating physician based on documented nerve symptoms, not on patient demand. The medical record showing the clinical indication is the appropriate evidence.

Challenge: "The prescription runs too long — the injury couldn't still be causing pain after a year."

Response: The physician continued prescribing because the clinical presentation continued to warrant treatment. Neuropathic pain from disc herniation, central sensitization, or peripheral nerve injury is not time-limited. Duration of prescribing is a medical judgment supported by clinical assessment at each visit.

[!WARNING] Attorneys should be prepared to address defense attacks on prescription duration and off-label use before they arise. Request a declaration from the prescribing physician explaining the clinical rationale if the defense demands it in discovery.

Pharmacy Lien Coverage for Gabapentin

Gabapentin is covered under pharmacy lien programs when prescribed by a treating physician for injuries related to the accident. At chronic dosing (1,800–3,600 mg/day, 2–3 fills per month for 6–12 months), gabapentin produces a meaningful cumulative lien amount.

For personal injury patients who cannot access or afford gabapentin through traditional insurance, a pharmacy lien program ensures continuous access without treatment gaps. Stopping and restarting gabapentin creates both clinical risk (potential withdrawal effects at high doses) and case risk (treatment gaps that invite defense attack).

[!KEY] Abrupt gabapentin discontinuation creates both clinical risk — withdrawal symptoms including rebound pain and anxiety — and legal risk, because a refill gap gives defense counsel a documented interval during which the physician apparently deemed treatment unnecessary; a pharmacy lien eliminates this cost barrier entirely.

Attorneys managing cases with gabapentin in the medication history should confirm that the client is reliably filling their prescriptions. If cost or insurance access is an obstacle, enrollment in a pharmacy lien program resolves it.

Key Takeaways for PI Attorneys

1. Gabapentin = nerve signal. When it appears in the record, it indicates the treating physician identified neuropathic involvement — a fact worth emphasizing in the demand.

2. Duration matters. A 12-month gabapentin prescription is stronger evidence than a 30-day trial. Note the full treatment duration in your demand narrative.

3. Off-label is routine. Physicians prescribe gabapentin off-label for traumatic neuropathic pain in standard clinical practice. The FDA approval is for postherpetic neuralgia — not a limitation on physician judgment.

4. Protect against treatment gaps. Gabapentin needs to be filled consistently. Use a pharmacy lien program to ensure your client never skips a fill due to cost.

5. Request the POGOS. If your client's medications are through LienScripts, a pharmacist-authored POGOS report ties the gabapentin history to the injury mechanism and supports medical necessity at demand.

Related Resources

• Gabapentin vs. Pregabalin for Personal Injury: Clinical Comparison
• Pharmacy Services for Personal Injury Clients: How It Works
• What Is a POGOS Report?
• Treatment Gaps and Medication Access
• Gabapentin for Whiplash Injuries

[!SOURCE] FDA Prescribing Information: Gabapentin Capsules (NDA 020235) — Approved indications, mechanism of action, dosing ranges, and contraindications for gabapentin.

[!SOURCE] DailyMed: Gabapentin — NIH/NLM drug label database entry for gabapentin including full prescribing information and clinical pharmacology.